2025年6月26日上午，山东省政府新闻办举行"矢志创新发展 建设科技强省"科技工作者系列记者见面会第二场，山东第一医科大学附属肿瘤医院放射肿瘤学 教授陈大卫先生作为代表之一，分享了他在放射肿瘤临床诊疗工作以及相关科研工作中的创新成果和惠民举措。 在谈到如何提升科技应用效率、降低临床诊疗费用以及让基层和欠发达地区的肿瘤患者受益时，陈大卫教授认为，第一是标准，让每一个病人接受到标准的 治疗。他们医院已经开始多学科协作，为每一个病人制定方案，运用了标准方案，就会少走弯路，治疗的费用也就用在了点儿上，是一种高效的方式。第二 是在标准的基础上拿出更好的方案，使病人在最短的时间内接受到最高性价比的方案。他们目前在做的研究，就是为了更好的治疗疾病，更多的为病人省 钱，这也是他们从事肿瘤相关研究的意义。 陈大卫教授主要从事放射肿瘤临床诊疗工作，以及放疗联合免疫治疗最佳应用模式、远隔效应机制相关研究的临床和科研工作。他带领团队运用大分割放疗 联合免疫治疗的模式，成功将既往治疗的有效率提高了一倍以上，并将晚期肺癌患者的生存期延长了近一倍。相关研究成果获得 2024 年国家科技进步奖二 等奖（山东省医疗卫生领域唯一）、中国青年五 ...

智通财经APP获悉，6月23日，中国肿瘤医疗服务领域的璀璨新星——佰泽医疗(02609)正式敲响港交所 的上市锣声，迎来资本市场首秀。上市首日，公司股价高开近25%，一路高歌猛进，收盘大涨超42%， 报收6.00港元，展现出市场对其发展前景的强烈信心。此次IPO，佰泽医疗以4.22港元的发行价，发行 了1.33亿股，成功募集到了约5.62亿港元的资金，为后续的发展注入了强大的动力。 肿瘤全周期服务领航者 高效运营驱动业绩腾飞 作为肿瘤全周期服务的领航者，佰泽医疗凭借差异化的"早筛+治疗+康复"肿瘤全周期服务战略迅速崛 起。专注于肿瘤全周期管理的佰泽医疗，精准地把握住了肿瘤医疗服务这一蓝海市场的机遇，以平台 化、一体化的医院运营管理模式，在医疗需求缺口较大的区域建立起竞争优势，展现出独特的增长潜 力。 在战略布局方面，佰泽医疗已在北京、天津、安徽、山西、河南五省市成功运营八家医院。通过持续投 入大量资源，公司在这些医院设立了早癌筛查中心和肿瘤康复中心，引入先进设备、培养专业人才，不 断提升肿瘤学科建设水平，强化行业竞争力。 而这种高效的运营模式，也为佰泽医疗带来了丰厚的财务回报。招股书显示，2022年至2024 ...

Group 1 - Baize Medical was listed on the Hong Kong Stock Exchange on June 23, 2025, becoming the third oncology medical service company to go public, following Haijia Medical and Meizhong Jiahe [1] - On its first trading day, Baize Medical's stock price opened at HKD 5.25, a rise of over 24% from the issue price of HKD 4.22, and closed at HKD 6.00, marking a gain of 42.18% [1] - The successful listing of Baize Medical may promote resource integration within the industry and support the expansion of the oncology medical service market [1] Group 2 - Pharmaron announced that its associate company, Yaojie Ankang, was listed on the main board of the Hong Kong Stock Exchange on June 23, 2025 [2] - Pharmaron holds approximately 5.78% of Yaojie Ankang's total shares after the listing, but the actual financial impact will be determined by the audit report [2] - The listing of Yaojie Ankang may enhance investment return expectations and demonstrate the effectiveness of Pharmaron's industry chain layout [2] Group 3 - Guanhao Biological announced the termination of its plan to issue shares to specific investors and has withdrawn its application documents due to changes in the market environment [3] - The decision reflects a strategic adjustment in financing, influenced by market conditions and the company's overall development plan [3] - Attention is needed on the subsequent funding arrangements and business progress following this decision [3] Group 4 - WuXi AppTec has completed a share buyback of 1.5775 million shares, amounting to a total of 1 billion yuan, which represents 0.5462% of its total share capital [4] - The repurchased shares will be used for cancellation, thereby reducing the registered capital [4] - This action signals confidence in long-term development and may enhance shareholder return expectations while optimizing the capital structure [4]

6月23日，佰泽医疗集团(Bayzed Health Group)(02609)于港交所主板成功上市。上市首日，公司股价表 现亮眼，盘中涨幅一度达到24.41%，受到资本市场热烈追捧。 佰泽医疗本次发行价为4.22港元，发售1.33亿股，募资总额约5.62亿港元。本次IPO的基石投资者为 Harvest Oriental，此次认购1.49亿港元，占总募资的26.5%，占全部发行后的股权比例为2.7%。 作为中国肿瘤全周期医疗服务的新贵，佰泽医疗的成功上市不仅标志着其作为中国肿瘤全周期医疗服务 领域新兴领军者的市场地位获得确认，更体现了资本市场对肿瘤医疗这一高成长性赛道的持续看好。公 司上市后的表现，将成为观察中国民营专科医疗服务发展的重要风向标。 癌症早筛市场千亿蓝海，谁主沉浮? 近年来，随着工业化进程加速、环境因素影响叠加人口老龄化趋势，我国癌症发病率持续攀升，肿瘤防 治形势日益严峻。根据国家癌症中心数据，2022年全国新发癌症病例达482.47万例，全癌种标化发病率 年均增长1.4%，恶性肿瘤相关年医疗支出已突破2200亿元;世界卫生组织(WHO)则在《2020年世界癌症 报告》中预测，未来20年全球癌症 ...

中国肿瘤医疗集团佰泽医疗下周一港股挂牌上市，行情显示，在目前的暗盘交易中涨近29%报5.44港 元；每手600股，不计手续费，每手赚732港元。 ...

Group 1 - The core viewpoint of the article highlights the significant opportunity for investors in the rapidly expanding private oncology medical market in China, as represented by the upcoming IPO of Baize Medical [1] - Baize Medical aims to address the challenges in China's oncology treatment landscape, characterized by an imbalance in medical resources and a mismatch between supply and demand [1][3] - The company has established a comprehensive "early screening + treatment + rehabilitation" service strategy, positioning itself favorably in the market with a differentiated growth potential [1][4] Group 2 - Baize Medical's competitive advantage lies in its accumulation of high-quality medical resources and its unique full-cycle oncology service system, which is scarce in the domestic market [3] - The company has formed strong strategic partnerships with top institutions, enhancing its operational capabilities and industry experience [3][4] - As of December 2024, all of Baize Medical's hospitals will have established early cancer screening centers and standardized rehabilitation centers, creating a closed-loop ecosystem for cancer care [4] Group 3 - Between 2018 and 2022, Baize Medical executed a precise acquisition strategy, acquiring five private hospitals and establishing a service matrix of six self-owned hospitals and two managed hospitals [7] - The company has demonstrated impressive post-acquisition integration capabilities, with outpatient visits increasing from 547,919 in 2022 to 833,000 in 2024, reflecting a compound annual growth rate of 23.3% [9][10] - Financially, Baize Medical's revenue grew from 800 million RMB in 2022 to 1.19 billion RMB in 2024, with a compound annual growth rate of 21.7% [11][12] Group 4 - The company has successfully crossed the breakeven point, with adjusted net profit reaching 12.5 million RMB in 2024, indicating strong growth potential and profitability certainty [13] - The current market conditions, including improved liquidity and a recovering IPO environment, provide a favorable backdrop for Baize Medical's listing [15][19] - The aging population and increasing demand for cancer prevention and treatment in China present a significant growth opportunity for Baize Medical's full-cycle oncology service strategy [21]

来源|贝多财经 6月13日，佰泽医疗集团有限公司（下称"佰泽医疗"，HK:02609）披露发售公告，于6月13日至6月18日招股，拟全球发售1.33亿股，预计将于2025年6月23日 在港交所上市。 据招股书介绍，佰泽医疗是一家主要从事投资及提供医疗相关服务的肿瘤医疗集团。目前，该公司通过6家民营营利性医院的直接股权所有权、2家民营非营 利性医院的管理权，在北京、天津、山西省、安徽省、河南省运营和管理8家医院。 其中，6家民营营利性医院指的是北京京西肿瘤医院、天津石氏医院、天津南开济兴医院、太原和平医院、合肥佰惠长荣医院、武陟济民医院，2家民营非营 利性医院则为黄山首康医院、太原市万柏林区和平小区卫生服务中心。 佰泽医疗在招股书中称，该公司专注于开展肿瘤相关医疗服务，包括但不限于对患者开展肿瘤诊断、多种手段的肿瘤治疗、肿瘤康复及临终关怀等，以及对 包括肿瘤患者家属在内的其他潜在健康人群开展的早癌筛查、肿瘤疫苗接种、健康管理服务。 自2023年3月起，太原和平医院由二级甲等综合医院升级为三级康复专科医院，成为山西省首家三级康复专科医院；自2024年4月起，武陟济民医院由二级甲 等综合医院升级为三级综合医院，成为 ...

｜2025年6月9日星期一｜ NO. 1香港证监会向环联国际发出限制通知书 6月6日，香港证监会向环联（国际）资产管理有限公司（以下简称环联国际）发出限制通知书，原因是对其可靠程度和诚信，以及能否称职 地、诚实地及公正地进行受规管活动，乃至是否继续持牌的适当人选存有疑虑。在6月6日的行动中，香港证监会搜查了包括环联国际的负责 人员所占用的处所。 点评：香港证监会向环联国际发出限制通知书，突显了对该公司在可靠程度、诚信以及是否能胜任规管活动的担忧。此举可能对环联国际的 声誉和业务产生重大影响，也反映了监管机构对市场参与者的高标准要求。市场参与者需严格遵守法规，确保市场公平、透明。 NO.2 香港证监会出手遏制违法金融网红活动 6月6日，香港证监会公告称，正联同全球各地的监管机构，携手遏制违法金融网红的活动。这些金融网红非法兜售金融产品或服务，让数以 百万计的社交媒体用户面临风险。金融网红是指那些利用社交媒体平台推广金融产品，并与追随者分享投资见解及建议的网络红人。 点评：香港证监会通过监察工作、执法行动及投资者教育等途径来维护市场廉洁稳健和保护广大投资者，有关工作的成效将会因为监管同业 之间的合作而大为提升。投 ...

Core Insights - The article highlights the significant breakthrough of Meizhong Jiahe (02453.HK) in the field of tumor precision diagnosis and treatment, particularly with the launch of its self-developed proton therapy vertical large language model [1][4] - The deployment of this model at Guangzhou Taihe Tumor Hospital marks a milestone in the intelligentization of tumor medical services, showcasing the company's strong technical capabilities and immense commercial potential [1][4] Company Developments - Meizhong Jiahe's subsidiary, Beijing Hexin Kang Technology Co., Ltd., established in 2015, focuses on improving medical services through artificial intelligence technology [1] - The proton large model is a pioneering achievement in the proton therapy vertical field, establishing industry technical standards and filling a gap in the market [1][3] Application and Impact - The proton large model has been successfully implemented at Guangzhou Taihe Tumor Hospital, which is the first clinical center in South China equipped with the Varian ProBeam proton radiation therapy system [2] - The model's training data is sourced from the hospital's clinical processes, ensuring accuracy and relevance, which enhances the efficiency of "human-machine collaboration" in treatment [2] Future Plans - The development plan for the proton large model extends beyond proton therapy, aiming to create an AI diagnostic matrix covering the entire lifecycle of tumor screening, diagnosis, treatment, and rehabilitation [3] - This approach allows Meizhong Jiahe to improve the efficiency and quality of its medical services while also enabling diverse collaborations with other medical institutions through technology licensing and remote diagnostic support [3] Market Position - As the first company in Hong Kong to engage in proton therapy, Meizhong Jiahe has established a strong competitive barrier in the tumor diagnosis and treatment sector [4] - The launch of the proton large model elevates the company's advantages, redefining industry standards and accelerating the intelligent transformation of the tumor medical industry [4]